Brian L. Claggett, Ph.D.
Affiliations: | 2012 | Biostatistics | Harvard University, Cambridge, MA, United States |
Area:
Biostatistics Biology, Statistics, EpidemiologyGoogle:
"Brian Claggett"Parents
Sign in to add mentor| Lee-Jen Wei | grad student | 2012 | Harvard | |
| (Statistical methods for clinical trials with multiple outcomes, HIV surveillance, and nonparametric meta-analysis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Peikert A, Vaduganathan M, Claggett BL, et al. (2024) Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER. European Journal of Heart Failure |
| Cunningham JW, Claggett BL, Lopes RD, et al. (2024) Daprodustat and Heart Failure in CKD. Journal of the American Society of Nephrology : Jasn |
| Minamisawa M, Inciardi RM, Claggett B, et al. (2024) Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON-HF study. European Journal of Heart Failure |
| Adamo M, Metra M, Claggett BL, et al. (2024) Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction. Jacc. Heart Failure |
| Vardeny O, Desai AS, Jhund PS, et al. (2024) Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. Jama Cardiology |
| Felker GM, Solomon SD, Metra M, et al. (2024) Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study. Journal of Cardiac Failure |
| Wang X, Lam CSP, Vaduganathan M, et al. (2023) Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial. Jacc. Asia. 4: 108-118 |
| Kondo T, Gasparyan SB, Jhund PS, et al. (2023) Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. Nejm Evidence. 2: EVIDoa2300042 |
| Mc Causland FR, Claggett BL, Vaduganathan M, et al. (2023) Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. Jama Cardiology |
| Kondo T, Butt JH, Curtain JP, et al. (2023) Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circulation. Heart Failure. e010898 |